PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
Turnover
16.67%
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
-15.11%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$96.6M
AUM Growth
-$25.4M
(-21%)
Cap. Flow
+$324K
Cap. Flow
% of AUM
0.34%
Top 10 Holdings %
Top 10 Hldgs %
32.65%
Holding
115
New
5
Increased
35
Reduced
28
Closed
10
Avg Time Held
3.8
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABTC
American Bitcoin Corp
ABTC
|
+$1.24M |
| 2 |
Magnite
MGNI
|
+$1.21M |
| 3 |
Fortress Biotech
FBIO
|
+$650K |
| 4 |
NeoGenomics
NEO
|
+$477K |
| 5 |
SRXH
SRX Global
SRXH
|
+$412K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATRS
Antares Pharma, Inc.
ATRS
|
+$1.97M |
| 2 |
LeMaitre Vascular
LMAT
|
+$1.95M |
| 3 |
International Flavors & Fragrances
IFF
|
+$563K |
| 4 |
AT&T
T
|
+$223K |
| 5 |
Costco
COST
|
+$219K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.9% |
| 2 | Technology | 19.64% |
| 3 | Communication Services | 8.2% |
| 4 | Consumer Staples | 7.55% |
| 5 | Industrials | 6.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Eli Lilly
LLY
$1.08T
| $4.35M | 4.5% |
13,408
| – | – |
2013 Q2
36 quarters
|
|
2
Microsoft
MSFT
$3.97T
| $3.98M | 4.12% |
15,493
| – | – |
2014 Q1
33 quarters
|
|
3
Idexx Laboratories
IDXX
$41.5B
| $3.79M | 3.92% |
10,805
| – | – |
2013 Q3
35 quarters
|
|
4
Abbott
ABT
$178B
| $2.94M | 3.05% |
27,080
| – | – |
2014 Q1
33 quarters
|
|
5
OptimizeRx
OPRX
$156M
| $2.94M | 3.04% |
107,230
-100
| -0.1% | -$2.96K |
2018 Q2
16 quarters
|
|
6
Inuvo
INUV
$7.9M
| $2.88M | 2.98% |
581,267
+764
| +0.1% | +$3.4K |
2018 Q2
16 quarters
|
|
7
Digi International
DGII
$2.73B
| $2.83M | 2.93% |
116,850
-600
| -0.5% | -$13K |
2020 Q1
9 quarters
|
|
8
Pfizer
PFE
$167B
| $2.78M | 2.88% |
53,023
-250
| -0.5% | -$12.7K |
2013 Q2
36 quarters
|
|
9
Veracyte
VCYT
$3.49B
| $2.55M | 2.64% |
128,130
+5,150
| +4% | +$104K |
2018 Q1
17 quarters
|
|
10
Axogen
AXGN
$2.08B
| $2.51M | 2.59% |
305,940
+17,750
| +6% | +$152K |
2013 Q3
35 quarters
|
|
11
Natera
NTRA
$57.5B
| $2.29M | 2.37% |
64,700
+6,300
| +11% | +$233K |
2018 Q2
16 quarters
|
|
12
DELISTED
Profire Energy, Inc
PFIE
| $2.24M | 2.32% |
1,554,380
-3,565
| -0.2% | -$4.79K |
2016 Q2
24 quarters
|
|
13
QuickLogic
QUIK
$176M
| $2.12M | 2.2% |
250,285
+3,503
| +1% | +$21.7K |
2019 Q2
12 quarters
|
|
14
DELISTED
Streamline Health Solutions
STRM
| $2.11M | 2.18% |
110,543
+66
| +0.1% | +$1.33K |
2018 Q2
16 quarters
|
|
15
Advanced Micro Devices
AMD
$934B
| $2M | 2.07% |
26,184
| – | – |
2018 Q1
17 quarters
|
|
16
Perion Network
PERI
$347M
| $1.88M | 1.95% |
103,351
-3,300
| -3% | -$68.4K |
2021 Q1
5 quarters
|
|
|
SRXH
17
SRX Global
SRXH
$25.9M
| $1.85M | 1.92% |
431
+88
| +26% | +$412K |
2021 Q2
4 quarters
|
|
18
AbbVie
ABBV
$501B
| $1.84M | 1.91% |
12,025
| – | – |
2019 Q1
13 quarters
|
|
19
Ooma
OOMA
$548M
| $1.77M | 1.83% |
149,675
-750
| -0.5% | -$9.96K |
2018 Q2
16 quarters
|
|
|
20
NeoGenomics
NEO
$2.17B
| $1.65M | 1.71% |
202,550
+50,000
| +33% | +$477K |
2013 Q2
36 quarters
|
|
21
Elutia
ELUT
$32.4M
| $1.6M | 1.66% |
226,729
-1,000
| -0.4% | -$6.46K |
2020 Q4
6 quarters
|
|
22
General Mills
GIS
$17.1B
| $1.6M | 1.65% |
21,175
-175
| -0.8% | -$12.3K |
2017 Q4
18 quarters
|
|
23
DELISTED
Cantaloupe
CTLP
| $1.51M | 1.57% |
270,125
+12,000
| +5% | +$63.7K |
2020 Q4
6 quarters
|
|
24
AtriCure
ATRC
$2.92B
| $1.4M | 1.45% |
34,350
| – | – |
2013 Q2
36 quarters
|
|
25
Exagen
XGN
$207M
| $1.36M | 1.41% |
236,975
+36,000
| +18% | +$210K |
2019 Q3
11 quarters
|
|
Similar funds
AA
WA
AC
BCVI
HAP
RHIG
CWM
SI
Perkins Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Perkins Capital Management held 115 positions worth $96.6M, down 21% from $122M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Perkins Capital Management's Q2 2022 filing shows 5 new, 35 increased, 28 reduced and 10 closed positions. Its largest new stake was American Bitcoin Corp: 72 shares worth $300K. The largest sale was Antares Pharma, Inc., an estimated $1.97M.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 57% a quarter earlier, followed by Technology and Communication Services.
- Perkins Capital Management's largest Q2 2022 buy was American Bitcoin Corp: 72 shares worth $300K.
- Perkins Capital Management added most to Magnite in Q2 2022, an estimated $1.21M increase.
- Perkins Capital Management's biggest Q2 2022 reduction was AT&T, cutting an estimated $223K.
- Perkins Capital Management fully exited Antares Pharma, Inc. in Q2 2022, selling an estimated $1.97M.
- Perkins Capital Management's ten largest holdings make up 33% of its $96.6M portfolio in Q2 2022.
- Perkins Capital Management opened 5 new positions and closed 10 in Q2 2022.
- Perkins Capital Management's portfolio value fell 21% quarter-over-quarter to $96.6M.
Based on Perkins Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.